Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.

Ann Oncol

Department of Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK.

Published: December 2021

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.annonc.2021.10.002	DOI Listing

Publication Analysis

corrigendum 'first-line

'first-line atezolizumab

atezolizumab nab-paclitaxel

nab-paclitaxel unresectable

unresectable locally

locally advanced

advanced metastatic

metastatic triple-negative

triple-negative breast

breast cancer

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!